AbbVie’s and Neurocrine Biosciences’ treatment for uterine fibroids successfully completes phase III trial

AbbVie and Neurocrine Biosciences announced that the second positive phase III trial was successful for their uterine fibroids drug elagolix, enabling another regulatory filing for the drug. Both companies are currently waiting for an FDA verdict in the US in the coming weeks on elagolix as a treatment for endometriosis-related pain, although uterine fibroids are

Continue Reading

Results of NIH study of asthma in children lead to cautions against short-term high-dose steroid treatment

US researchers have found that a common practice among physicians to increase the use of steroids for worsening symptoms of asthma in children could be linked with slowing a child’s rate of growth. Results of the study found that temporarily increasing the dosage of inhaled steroids when asthma symptoms begin to worsen, not only has

Continue Reading

Are we daring to fail spectacularly?

Yvette Cleland comments on the latest Clinical Professionals Industry Analytics report, 2017 in review: “In a landscape of profound uncertainty, last year saw record levels of investment in the UK life sciences industry. With £2.4 BN raised in IPO’s and further offerings, 2017 saw a 20% increase in investment when compared to 2016. So, are

Continue Reading

Clinical Professionals Group and the Apprenticeship Levy

Whilst many are concerning themselves with the UK’s ‘Brexit’ from the EU and the potential negative impacts, Clinical Professionals’ Academies team have been focussing on the positive movements by government to create talented and skilled professionals through apprenticeships to bolster our Life Science economy – something we know a lot about and have been evangelising

Continue Reading

Novartis’ psoriasis trial data for Cosentyx outshines Johnson and Johnson competitor

Novartis has recently released trial data showing that Cosentyx was shown to be significantly more effective in treating patients with psoriasis when compared to the Johnson & Johnson’s rival biologic Stelara. According to the published results from the head-to-head CLARITY study, 66.5% of patients treated with Cosentyx achieved the primary endpoint PASI 90 (a 90%

Continue Reading

UK Biotech given green light to begin stem cell therapy clinical trial for heart failure

UK biotech, Celixir, has received a green light to start a phase IIb trial of HeartCel, its stem cell-based therapy for heart failure, that could potentially support approval. Heartcel is a preparation of off-the-shelf immunomodulatory progenitor (iMP) cells that are injected around cardiac scar tissue during coronary artery bypass graft (CABG) surgery in the hope

Continue Reading